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Abstract 
 
To be added 
 
 
Introduction 
 
The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as 
a primary or secondary outcome measure in clinical trials of systemic sclerosis (SSc). 
This article gives a brief history of mRSS development, outlines practical aspects of 
assessing mRSS in clinical trials, and provides recommendations for Phase 2 and 3 
clinical trials where the measurement of skin thickness is the primary or a secondary 
outcome measure. 
 
Natural history of skin involvement in SSc 
 
SSc is subclassified into “diffuse cutaneous” or “limited cutaneous” based on the extent 
of skin involvement. In diffuse cutaneous SSc (dcSSc), it is generally accepted that the 
mRSS tends to worsen in early disease and decrease in late disease, although the time 
of peak involvement remains poorly defined. “Early” dcSSc is often defined as the 
period of rapidly and severely increasing induration (“thickening”) of the skin, which has 
been thought to peak 1.5-5 years after onset of the disease. Skin involvement in dcSSc 
usually goes through 3 phases: 1. An edematous phase that usually lasts 6-12 months, 
a fibrotic or indurative phase that lasts from 1-4 years or longer, and an atrophic phase, 
that lasts for rest of the patient’s life . (Figure xxx). The duration of different phases may 
differ in each individual patient.  The time to peak MRSS in a cohort of dcSSc has been 
described previously and helps inform definitions of early skin disease (see: Nihtyanova 
SI, Denton CP. Current approaches to the management of early active diffuse 
scleroderma skin disease. Rheum Dis Clin North Am. 2008 Feb;34(1):161-79; viii. doi: 
10.1016/j.rdc.2007.11.005.). 
 
Measurement of skin thickness is used as a surrogate measure of disease severity and 
mortality in patients with dcSSc—an increase in skin thickening is generally associated 
with involvement of internal organs and increased mortality (Clements D Pen; Shand 
AR). In addition, the trajectory of worsening of mRSS is associated with worse 
outcomes, including higher mortality (Domsic ARD). The change  in mRSS is 
associated with change in mortality, renal and cardiac outcomes ( Clements PJ, Hurwitz 
EL, Wong WK et al. Skin thickening score as a predictor and correlate of outcome… 
A&R 2000. 43:2445-2454; Marco PJ, Weisman MH, Seibold JR, Furst DE et al. 
Predictors and outcomes of scleroderma renal crisis. A&R 2002. 46:2983-2989).. Some 
nuance was added by Shand L  et al who showed that outcomes were particularly 
associated with the prior trajectory of skin thickening(Shand L, Lunt M, Nihtyanova 
S,Hoseini M et al. Relationship between change in skin score and disease outcome in 
diffuse cutaneous systemic sclerosis. A&R 2007. 56: 2422-2431)  In addition, those 
cases that never achieved a high skin score had lower frequency of major organ based 
complications and those with high skin scores that failed to improve by 3 years of 
disease has significantly higher mortality, implying that attenuation of peak skin score or 
improvement may reflect better outcome.  This point is noteworthy as we need to 
emphasize the potential benefit of including milder or early cases - both a preventative 
as well as an improvement strategy for clinical trials and future clinical practice. 
CD: I am sure Oliver will add something good here about the EUSTAR analysis and cohort 
enrichment. 
 
Historical perspective  
 
Phil: I did the above.this one is yours, ok? DF 
 
mRSS as an outcome measure 
 
mRSS meets the OMERACT filters of truth, discrimination, and feasibility. This has 
been detailed by Merkel et al and the readers are encouraged to review the OMERACT 
proceedings. Briefly, mRSS has the following characteristics. 
a. Feasible—easy to do with little equipment and requires little time  
b. Face Validity—captures skin thickness  
c. Content Validity— covers the affected body areas in SSc 
d. Construct validity—correlates with other measures of SSc such as 
durometer and ultrasound (ref) 
e. Criterion Validity—reflects gold standard-biopsy (ref) 
f.  Sensitivity to change—analysis of multicenter clinical trials show change 
over time. For example, the MRSS was able to differentiate between 
treatment with methotrexate and placebo in early diffuse SSc and between 
cyclophosphamide and placebo in the diffuse SSc subset in the 
Scleroderma Lung Study-I. The MRSS also improved in the Autologous 
Stem Cell Transplant Study and showed a trend towards improvement for 
tociluzimab. 
 
 
 
Conducting mRSS in clinical trials 
 
Practical aspects 
 
1. Positioning of the patient: This is an important part of assessing mRSS and 
should be done in a relaxed fashion. Figure xx shows proper positioning of the 
patient for conducting mRSS. We recommend that the patient be in sitting a 
relaxed position with arms by the side of the body when examining upper 
extremities, face, and chest. We recommend that the patient lie down on a bed 
while examining the abdomen and lower extremities, with the hips at 45 degrees 
flexion and dorsi flexion of the feet. The point is that the muscles underlying the 
areas of skin be relaxed or there is a danger of falsely elevated skin scores. 
2. Assessing skin thickness: There are 2 techniques to accomplish this by 
palpation of the skin(Figure xx). 
a. Index finger and thumb. This is preferred method where the skin is rolled 
gently to gauge thickness.  
b. The other method is to use two thumbs to form a fold of skin between 
advancing lateral thumb borders and may be easier when skin overlies 
bone such as the fingers and the dorsum of the hands. 
c. It is important to understand the relative distribution of fat and underlying 
structure as it can make the skin thickness feel differently in different 
anatomical areas.  
d. Skin should be scored based on how the skins feels and not how it 
looks. For example, shiny skin, usually over the chest, doesn’t mean that 
skin has increased thickness. 
 
Global average vs. maximum score of an anatomic area—There are 
differences in scoring mRSS in clinical practice but we recommend 
standardizing mRSS measurement in clinical trials. We propose to 
average the score of a given anatomic area (Figure xx). This has been 
successfully used in previous clinical trials. In addition, there is theoretical 
disadvantage of using maximum score over an anatomic area as it may 
limit sensitivity to change. Consider an area over forearm [as an example] 
that remains a 3 but the skin improves overall. Using maximum score, this 
will continue to be scored as mRSS of 3 but the global average will 
change (improve) over time as it incorporates the whole area.  One point 
for clarification is that if an area of skin in one of the 17 sites has grade 1 
but no more severe thickening is in that site then the score of 1 is given – 
i.e. for global average maximizing applies in this situation. 
3. Scoring of each individual body area (Figure xx) 
a. mRSS =0 is defined as normal skin where the assessor can appreciate 
fine wrinkles and appreciable skin thickness appreciated 
b. mRSS =1 Appreciate skin thickness and easily able to make the skin fold 
between 2 fingers and may demonstrates fine wrinkles. mRSS=0 vs. 1 
depends on the feel of the skin  
c. mRSS =2 Appreciate skin thickness with difficulty in making skin folds and 
unable to appreciate wrinkles 
d. mRSS =3 Appreciate skin thickness with inability to make easy skin folds 
between 2 fingers 
 
4. Same examiner should evaluate the patient during the trial: Each outcome 
measure inherently has measurement variability. It is recommended that same 
assessor examine the patient during the duration of the trial. The inter-observer 
variability of mRSS is 4.6 units (coefficient of variation=25%) and the intra-
observer variability is 2.5 unites (coefficient of variation= 12%). Although the 
mRSS has been considered less than satisfactory outcome measure by 
rheumatology community, in a study assessing inter-observer variability of joint 
and tender joint count in rheumatoid arthritis, the coefficient of variation was 82% 
for swollen joints and 66% for tender joints (Scott et al Clinical Rheumatology 
1996).  
 
5. Teaching reduces variability of mRSS (Laszlo and Dan) The mRSS is a 
validated outcomein diffuse SSc but, as in rheumatoid arthritis, training of the  
measure is important. In a 12 investigator teaching course, the ICC was 0.639, a 
very good reliability. On repeat training 7 months later, the ICC was 0.684, 
essentially the same number. This seems to indicate that repeated retraining 
over time is not necessary(at least over 7 months). On the other hand, the other 
hand, inter-investigator variability was high at both training sessions( standard 
deviation: 3-5-5.3) emphasizing the need to  have the same investigator 
consistently measuring the same patient. 
 
 
6. Caveats in mRSS measurement 
a. The edematous phase of dcSSc is usually associated with non edematous 
pitting of the skin. mRSS may be difficult to assess and has been shown 
to be inaccurate with a correlation between an edema score and edema 
on biopsy of 0.069-0.169( ibid Furst, ClementsPJ, Steen VD et al). There 
is no agreed upon approach to this issue (altho some score one lower 
than the apparent score if there is edema( 3+ becomes 2+ etc, even 
including 1+ becoming 0 ))  
b. Tethering or hidebinding is defined as involvement of underlying tissues 
[such as fascia and muscles] over an anatomic area [generally fingers and 
dorsum of the hands] . mRSS does not score tethering. A UCLA 
developed score is generally agreed to measure tethering rather than 
thickness or, at least ,cannot differentiate tethering from thickening. It is 
not surprising that it is less sensitive than the mRSS, although it has 
changed in a trial of methotrexate  for SSc (Sultan N, Pope JE,Clements 
PJ et al. The HAQ is strongly predictive of good outcome in early diffuse 
scleroderma. Rheum(Oxford).2004.43:472-478.) 
c. Atrophic skin should be given a mRSS of 0 (Figure xx) 
 
7. Other aspects 
a. Variability within different races/ countries and paediatric population Masa 
and Ivan to write and others add to this 
 
 
  
Recommendations for assessing mRSS in clinical trials 
 
Phase 3 trial focused on mRSS as primary outcome measure or key secondary 
outcome measure 
 
Training is strongly encouraged for standardization of mRSS. 
We recommend 2 phases for training. 
 
 2   Teaching phase:  This should be conducted by an expert, following points should 
be made in 1-  2 patients with SSc 
 1. Show proper technique of performing MRSS including keeping body parts in 
relaxed position and highlight most likely involved areas.  
 2. mRSS should be performed based on the  ‘average’ method , 
assigning individual areas with a score that is most representative of the area 
under examination (For example, if the distal forearm has a patch considered 
2+ whereas the remainder of the forearm is 1+, then 1+ would be the most 
representative score. Alternatively, if the area rated 2+ was relatively 
extensive, then 2+ would be the recommended score for the forearm).  
          3. Skin should be scored based on how the skins feels and not how it   
           looks. Shiny skin, usually over the chest, doesn’t mean that the skin is thick. 
 4. Each site for the skin involvement (dorsum of the hand, forearm) should be 
scored from 0 to 3. Tethered skin areas, for purpose of skin scoring, should be 
scored as 0 as it is usually associated with atrophic skin. 
 
This should be followed by an Evaluation phase where each assessor should 
preferably score 3 patients with SSc. These patients should be different than the 
training patients and preferably reflect the inclusion criteria for the proposed trial. 
1. The experts should examine each patient and reach a consensus score.  
2. Trainees should be given the mRSS sheet (Figure xx and hyperlink for 
downloadable copy) and asked to examine each patient. 
3. Due to the measurement variability in mRSS, we recommend the following 
criteria for certification for the clinical trial. 
a. if the trainee is within +/-5 units of the experts’ score for all 3 patients, then 
the trainee has passed the Evaluation phase.  
b. if the trainee is within +/-5 units of the experts’ score for 2 of 3 patients, then 
the expert should review the disparity with the trainee and clarify concerns and 
the trainee preferably be asked to review mRSS training video and then 
considered to have passed the Evaluation phase. 
c. if the trainee is within +/-5 units of the experts’ score for 1 of 3 patients, then 
the trainee should repeat the training, either on the same day or another 
venue. 
  
  
All results should be documented for quality control and each trainee should receive a 
certificate at the end of training that should be part of the regulatory binder for the 
trial. 
 
 
Phase 3 trial where mRSS is a secondary outcome measure or in a Phase 2 
focused on mRSS as the primary outcome measure or key secondary outcome 
measure 
 
It is encouraged to use the aforementioned plan for standardization of the mRSS but we 
acknowledge the costs associated with training each assessor. In lieu of this, consider 
training at the investigator meeting where the above points should be discussed and a 
video or live demonstration should be performed and the trainee should be provided 
enough time for clarifications. Even in this situation, at least one patient should be 
scored under the supervision of an expert so that clarity of the methods can be 
achieved. Each trainee should receive a certificate at the end of investigator meeting 
that should be part of the regulatory binder for the trial.  
 
Finally, we recommend to discuss the above mentioned guidance with the regulatory 
agencies. 
 
 
 
